November 11, 2026- Lumos Diagnostics Holdings Ltd received confirmation that WellStreet Urgent Care (“WellStreet”) will expand the standardized adoption of FebriDx® across its network of more than 200 urgent care locations. FebriDx® is a rapid point-of-care test that uses a fingerstick blood sample to aid in the differentiation between bacterial and non-bacterial infection.
On October16, 2025, Lumos announced that it had entered into a single site pilot agreement with WellStreet to advance testing and reimbursement pathways for FebriDx® through WellStreet’s joint venture with Piedmont Healthcare in Atlanta, Georgia.
Following the success of the pilot program and subsequent to the U.S. Food and Drug Administration (U.S. FDA) granting CLIA waiver for FebriDx® on 27 March 2026, WellStreet and Lumos announced on 14 April 2026 that they would expand the program to an additional 43 locations within WellStreet’s network of urgent care clinics in Michigan and Georgia.
Building on the success of the program, WellStreet has now elected to expand the standardized adoption of FebriDx® to a total of 141 locations across Ohio, Georgia and Michigan. In addition, Lumos and WellStreet anticipate that expansion will continue and FebriDx® will be offered across all WellStreet locations (200+) in the near future.
Under a protocol implemented by WellStreet, FebriDx® will be offered to patients presenting with ARI symptoms. Test results will be available to the provider prior to entering the examination room, enabling faster clinical decision-making and more timely diagnosis and treatment of patients. WellStreet estimates that 70-80% of patient visits are related to acute respiratory infection during cold and flu season.
“FebriDx has become a valuable tool to our clinicians during this pilot period, augmenting their ability to appropriately diagnose and treat patients with acute respiratory illnesses. Along with patient and clinician satisfaction, we have seen measurable improvement in antibiotic stewardship that can be attributed to the introduction of this test in our centers. We are excited to expand access to FebriDx® testing and the associated benefits to our patients and the healthcare system at large in the coming weeks.” Brian S. Bobb, M.D., Senior Medical Officer – WellStreet Urgent Care
“The decision by WellStreet, one of the leading urgent care operators in the U.S., to standardise FebriDx® within its triage protocols across additional locations is a strong endorsement of the product’s clinical value. FebriDx® helps physicians make more informed, data-driven decisions at the point of care, supporting both improved patient management and responsible antibiotic stewardship.” Doug Ward, CEO, Lumos Diagnostics